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Abstract
Purpose This study examined real-world long-term use of
guideline-recommended bone targeted agents (BTA) among
patients with metastatic solid tumors.
Methods Adults with a solid tumor diagnosis followed by a
bone metastasis diagnosis in 2012–2014 were identified from
electronic medical records in the Oncology Services
Comprehensive Electronic Records (OSCER) database.
Patients initiated zoledronic acid (ZA) or denosumab on or
after the bone metastasis diagnosis and were followed through
last clinic visit by 30 June 2015. We describe time to BTA
initiation, compliance (≥12 administrations in a year),
switching, and non-persistence (switch or ≥90 day gap in ther-
apy), by agent and follow-up period.
Results The majority of the 14,881 study patients (50% fe-
male, 65% age ≥65 years) had breast (33%), prostate (26%),
or lung (26%) tumors. Half of all patients initiated on each
agent, with denosumab initiations exceeding ZA initiations in
2014. Most (91% denosumab, 93% ZA) initiations occurred
within 3 months of bone metastasis diagnosis. At 1, 2, and
3 years post-initiation, denosumab patients were less likely to
switch agents (4, 3, and 1% versus 14, 12, and 11%) and more
likely to be compliant (50, 37, and 31% versus 41, 26, and
6%). Median time to non-persistence was 25.9 months for
denosumab and 17.2 months for ZA, p < 0.0001.
Conclusions This is the first study reporting long-term treat-
ment patterns for the two primary BTAs used in the USA. The
greater compliance and longer persistence observed among
denosumab patients may improve treatment effectiveness
achieved in the real-world setting.
Keywords Bonemetastasis . Solid tumor . Bone targeted
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Introduction
Bone metastases are a common outcome in patients with solid
tumors and are present in up to 70% of patients with advanced
breast and prostate cancer and more than one third of patients
with advanced lung cancer [1]. Bone metastases are clinically
important because they increase the risk for a variety of debil-
itating skeletal-related events (SREs), including spinal cord
compression, bone surgery, pathologic fractures, and severe
bone pain requiring palliative radiotherapy [2, 1]. These
events are common with observational studies reporting a 1-
year incidence of SREs at 46% in prostate cancer patients and
38% in female breast cancer patients [3, 4] and clinical trials
reporting a 2-year cumulative incidence of 49% in prostate
cancer patients and 68% in breast cancer patients who were
not receiving treatment for bone metastases [5, 6]. Experience
in routine clinical practice (January 1995 to December 2009)
in two large health systems in the United States (US) suggests
that 63, 59, and 52% of breast, lung, and prostate cancer pa-
tients, respectively, experience an SRE either at diagnosis or
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during follow-up (median follow-up months: 13.6, 3.1, 16.6)
[7].
SREs that occur subsequent to bone metastases in patients
with solid tumors are associatedwith shortened survival [3, 4].
In addition, patients report poorer health status and lower
health-related quality of life following an SRE, and these
events impose a significant economic burden on patients and
the health care system overall through increased use of health
services including surgical interventions, as well as office
visits and medications to address SRE-related pain [8, 9].
Over the last decade, bone health has become an important
component of guideline-recommended care for patients with
solid tumors [10–12]. Since 1996, the US Food and Drug
Administration (FDA) has approved three bone targeted
agents (BTA) for use in prevention of SREs in patients with
bone metastasis secondary to solid tumors. These include zo-
ledronic acid (4 mg) and pamidronate disodium [13], both of
which are intravenous bisphosphonates (IVBP) with dosing
every 3–4 weeks and denosumab (120 mg), a RANK ligand
inhibitor [14] with dosing every 4 weeks. With its FDA ap-
proval in 2002, zoledronic acid became the predominant
IVBP for treatment of bone metastasis in the US, in part be-
cause it offers a shorter infusion time (a minimum of 15 min)
compared with that of pamidronate which requires at least
2 hours [15]. In 2010, the treatment landscape changed again
when the FDA approved denosumab for prevention of
skeletal-related events in patients with solid tumors. As a
first-in-class RANK ligand inhibitor, this agent offers a more
efficient, subcutaneous mode of administration which appeals
to patients as well as physicians [16, 17].
These agents represent important treatment options and are
included in clinical guidelines for patients with advanced solid
tumors; yet, there is limited literature describing their use in
routine practice in the US [18–20, 10]. The most recent data
from these studies report the experience of patients who initi-
ated BTA treatment through 2011, with follow-up periods of
up to 12 months. Changes in the cancer treatment landscape
are leading to increased survival even among patients with
advanced cancer, and extended use of supportive care is likely
to be more common. The current study examines BTA use
among patients with metastatic solid tumors who initiated a
BTA between 2012 and 2014.
Methods
This study used data from the Oncology Services
Comprehensive Electronic Records (OSCER) database which
includes electronic medical records (EMRs) from >750,000
cancer patients treated at >500 US community and hospital-
affiliated oncology clinics, since 2004. These clinical practices
include all payer types (commercial, Medicare, Medicaid, oth-
er, and cash) and patients residing in all 50 states. At each
patient visit, data on diagnoses and treatments including out-
patient chemotherapy and BTA administrations are captured
in the EMR and entered in to the database.
From the OSCER database, patients with a bone metas-
tasis diagnosis (International Classification of Disease
Coding Manual [ICD-9-CM] code 198.5) between 1
January 2012 and 31 December 2014 were identified.
Included patients were also required to have evidence of
a solid tumor, excluding multiple myeloma, as indicated by
the presence of at least one record with a relevant ICD-9-
CM diagnosis code on or prior to first identified bone me-
tastasis diagnosis. Patients were also required to be 18 years
of age or older as of the bone metastasis diagnosis. This
study focuses on patients who used either zoledronic acid
or denosumab since these are the predominant BTAs in
current use in the US. Patients in the study population
received their first administration of either zoledronic acid
or denosumab on or after the bone metastasis diagnosis
with a lookback period of 6 months to ensure that they
were incident BTA users. Compliance and persistence out-
comes were assessed during the first, second, and third
year after BTA initiation, among patients with data avail-
able for the entirety of each of these follow-up periods.
Demographics (age, sex, race/ethnicity) and disease char-
acteristics (location of primary solid tumor, time since cancer
diagnosis, time since bone metastases diagnosis) of study pa-
tients were captured as of the date patients initiated BTA (in-
dex date). Patients were followed for up to 36 months after
BTA initiation, with follow-up censored at the last clinic visit
recorded in OSCER by 30 June 2015. The average number of
BTA administrations and percentage of patients who received
at least 12 administrations in a year were determined for pa-
tients with follow-up in each of the three 1-year intervals
encompassed in the study period. This latter measure serves
as a proxy for compliance given the expectation that adminis-
trations should occur in 3–4-week intervals. Switching be-
tween agents was also assessed for patients with follow-up
in each of the three 1-year intervals. Non-persistence with
BTA therapy was assessed over 36 months of follow-up using
a previously published definition [21] of a gap in therapy of
90 days or longer, or 90 days or longer gap between the last
dose and the end of follow-up, or switch from the initial agent.
Sensitivity analyses were also performed using 60- and 120-
day therapy gaps to define non-persistence. Kaplan-Meier
analysis was used to describe the probability of non-
persistence during follow-up, and time to non-persistence
was defined as the time from the index date to the date of first
occurrence of non-persistence. Statistical analysis was per-
formed using SAS® software for Windows, version 9.2
(SAS Institute Inc., Cary, North Carolina). Test statistics (P
values) were generated using t tests for continuous variables
and Chi-square tests for categorical variables; no adjustments
were made for multiplicity.
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Results
The study included 14,881 patients (Supplemental Fig. 1) who
met all selection criteria. Of these, 50% were female and 65%
were aged 65 years or older (Table 1). The majority of patients
had breast (33%), prostate (26%), or lung (26%) tumors. The
number of patients included in the study increased each year
from 4106 (28%) in 2012 to 5059 (34%) in 2013 and to 5716
(38%) in 2014. Overall, approximately half of study patients
initiated on denosumab (49%) and half (51%) on zoledronic
acid. The percentage of patients who initiated on denosumab
increased over the study period and, in 2014, exceeded that of
patients initiating zoledronic acid (Fig. 1).
The demographic and clinical characteristics of patients
who initiated denosumab differed from those of patients
who initiated zoledronic acid (Table 1). Denosumab patients
were more likely to be older and also more likely to be male,
which reflects the fact that patients with prostate cancer com-
prised a larger proportion of the denosumab patient group than
of the zoledronic acid patient group (30.4% versus 21.0%,
p < 0.0001). Patients with breast cancer comprised a similar
proportion of the patients using each agent (p = 0.39). Patients
with lung cancer and those with other types of solid tumors
(i.e., non-breast, non-prostate, non-lung) represented a smaller
proportion of denosumab patients than of zoledronic acid pa-
tients (22.3% versus 29.4%, p < 0.0001; 14.4% versus 15.9%,
p = 0.01).
The distribution of patients by time between cancer diag-
nosis and BTA initiation differed between the denosumab and
zoledronic acid patients, although the magnitude of these dif-
ferences was small (Table 1). This was also the case for the
time between bone metastasis diagnosis and BTA initiation.
Overall, the majority (92%) of patients initiated BTA within
Table 1 Characteristics of patients with bone metastases secondary to solid tumors who initiated a bone-targeted agent in 2012–2014






Male 7407 (49.8) 3804 (52.2) 3603 (47.5) <0.0001
Racea/ethnicity: Asian 192 (1.5) 78 (1.2) 114 (1.7) <0.0001
African American 939 (7.2) 414 (6.5) 525 (7.9)
Other race 1397 (10.8) 583 (9.2) 814 (12.3)
White 10,445 (80.5) 5283 (83.1) 5162 (78.0)
Tumor characteristics
Location of primary tumor
Breast 4914 (33) 2384 (32.6) 2530 (33.4) 0.39
Prostate 3816 (25.6) 2220 (30.4) 1596 (21) <0.0001
Lung 3856 (25.9) 1626 (22.3) 2230 (29.4) <0.0001
Other solid tumors 2251 (15.1) 1048 (14.4) 1203 (15.9) 0.01
Multiple primary tumors 44 (0.30) 16 (0.22) 28 (0.36) —
Time from cancer diagnosis to BTA initiation
<1 year 9897 (66.5) 4766 (65.3) 5131 (67.6) 0.01
1–2 years 1420 (9.5) 710 (9.7) 710 (9.4)
≥2 years 3564 (24) 1818 (24.9) 1746 (23.0)
Time from bone metastasis diagnosis to BTA initiation
<1 year 14,582 (98) 7125 (97.7) 7457 (98.3) 0.02
1–2 years 261 (1.8) 150 (2.06) 111 (1.5)
≥2 years 38 (0.3) 19 (0.26) 19 (0.2)











Fig. 1 BTA initiations by agent and year
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3months of the bonemetastasis diagnosis. Ninety-one percent
of denosumab patients initiated within 3 months compared
with 93% of zoledronic acid patients, and the percentage of
patients initiating within 6 months was similar between the
two patient groups (95 and 96%, respectively).
The average number of BTA administrations per patient
overall was highest in the first year of follow-up and higher
in all follow-up periods for denosumab patients compared
with patients treated with zoledronic acid (Fig. 2). Patients
treated with denosumab were also more likely to remain com-
pliant, that is to receive at least 12 administrations in a 1-year
period (Fig. 3). When results were analyzed by tumor type,
treatment initiation and use patterns were similar to those for
the full solid tumor population.
Patients using denosumab were also less likely to switch to
zoledronic acid than vice versa (Fig. 4). In the first year of
follow-up, the percentage of patients switching agents was 4%
for denosumab patients versus 14% for patients using zoledro-
nic acid. In the second and third years, 3 and 1% of
denosumab patients switched compared with 12 and 11% of
patients using zoledronic acid. Among patients using
denosumab, 77, 54, and 38% were persistent at 12, 24, and
36 months of follow-up (Fig. 5). By comparison, persistence
among patients using zoledronic acid was 64, 36, and 23% in
each of these intervals. Regardless of the therapy gap used
(60, 90, 120 days), persistence was higher among patients
using denosumab than among patients using zoledronic acid.
Using the 90-day therapy gap, the median time to non-
persistence over the entire 36-month follow-up was
25.9 months for denosumab and 17.2 months for zoledronic
acid, p < 0.0001.
Discussion
This study updates previous studies of real-world BTA treat-
ment patterns among advanced solid tumor patients with more
recent data (BTA initiations between 1 January 2012 and 31
December 2014) and provides a long-term perspective by ex-
amining utilization in 1-year intervals for up to 3 years of
follow-up after BTA initiation. Thus, we aimed to reflect uti-
lization in current practice at US oncology clinics, in the pe-
riod during which physicians and patients have gained signif-
icant experience with the most recently approved BTA,
denosumab.
Although two recent administrative claim based studies
have examined treatment patterns for IV BP in solid tumor
patients beyond 1 year [19, 20], the only study to include all
available treatment options reported BTA treatment patterns
observed in the Oncology Services Comprehensive Electronic
Records (OSCER) for patients with solid tumors whose first
bone metastasis was diagnosed in 2011, with a maximum of
12-month follow-up [18]. The current study adds to these
previously reported results by examining BTA treatment pat-
terns for the two most commonly used agents, denosumab and
zoledronic acid, over up to 3 years of follow-up.
Results of the current study indicate that the majority of
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Fig. 2 Average number of BTA administrations by agent and follow-up
period
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bone metastasis diagnosis which is consistent with previously
reported findings [20, 18]. However, this finding should be
interpreted with caution. As Oster et al. note, SREs may
be the catalyst for the initiation of BTA therapy, since in
that study, similar percentages of breast cancer and pros-
tate cancer patients initiated IV BP prior to and after
experiencing their first skeletal complication [19].
Furthermore, the recording of bone metastasis diagnosis
may commonly be delayed until treatment is initiated. In a
validation study of the OSCER data among breast cancer
patients, a median of 32 days was found in between the
true date of bone metastasis diagnosis (per patient chart),
and the date diagnosis was coded in the electronic medical
record data, with a median delay of 43 days observed for
administrative claim data [22]. This delayed reporting
would therefore cause an underestimation in the time be-
tween initial diagnosis and treatment initiation.
Characteristics of patients who initiated on denosumab dif-
fered in some respects from those of patients who initiated on
zoledronic acid. Compared with patients initiating zoledronic
acid, denosumab patients were older. Although our study did
not examine treatment initiation rates, previous studies have
reported that the IV BP initiation among patients with bone
metastases varies with age and is significantly lower among
patients aged 65 and older compared with younger patients
[20, 19]. Additional research would need to be undertaken to
determine if the approval of denosumab has improved the
bone metastasis treatment rate among older patients since
the current study does not provide insights into whether treat-
ment rates in this important patient subgroup are changing
over time.
Compliance and persistence are important dimensions
of medication use and shape the therapeutic benefit that
patients may achieve. For our study, compliance was de-
fined as 12 or more administrations in a 12-month period,
although compliance to a strict 4-week dosing schedule
would yield 13 administrations in a year. In each of the
three 1-year periods evaluated, a greater percentage of
denosumab patients were compliant compared with zole-
dronic acid users. In the third year of follow-up, compli-
ance exceeded 30% among denosumab patients in con-
trast to 6% among patients using zoledronic acid. This
consistently greater compliance observed throughout the
3-year study period confirms and extends the 1-year find-
ings reported by Hernandez et al. As suggested previous-
ly, the better compliance among denosumab patients may
reflect more convenient dosing and physicians’ motiva-
tion to sustain Bon-time^ dosing schedules in order to
achieve the full therapeutic benefit demonstrated in the
denosumab clinical trials. Recent research into physician
preferences for bone metastasis drug therapy indicates that
the most important considerations are delaying SREs and
worsening of pain, while minimizing the risk of renal
impairment [16, 23]. Renal toxicity is also an important
factor when patients consider BTA therapy, and the
known renal toxicity of IV BPs complicates treatment
since renal function must be closely monitored in patients
using zoledronic acid and doses may be delayed or
skipped depending on the patient serum creatinine levels
[16, 24, 25]. That level of monitoring is not required for
denosumab which may also make compliance with
denosumab easier to achieve, particularly among patients
with complicated regimens of oncologic and supportive
therapies, regardless of age.
In addition to demonstrating higher compliance,
denosumab patients in our study also remained persistent with
therapy longer than patients using zoledronic acid (median
time to nonpersistence: 25.9 months versus 17.2,
p < 0.0001). The persistence rates for denosumab were 77,
54, and 38%, while persistence rates for zoledronic acid were
64, 36, and 23%, at 12, 24, and 36 months of follow-up,
respectively. Other researchers have also shown that persis-
tence is challenging for patients using IV BP. Hagiwara et al.,
for example, estimated that 46% of breast cancer patients,
56% of prostate cancer patients, and 83% of lung cancer pa-
tients had discontinued IVBP therapy at 12 months after IV
BP initiation [20].
Outside of clinical trials, treatment persistence with
BTA may vary, and several retrospective studies of ad-
ministrative claim data have documented better treatment
effectiveness for IV BP among patients with longer per-
sistence, although comparison of results is challenging
since definitions of non-persistence vary. In one such
study in which non-persistence was defined as a therapy
gap of more than 45 days, persistent use of monthly zo-
ledronic acid for 18 months was associated with a 50%
lower risk of an SRE and a 63% lower risk of a fracture
compared with persistent monthly use for less than
3 months among breast cancer patients [26]. In two other
Fig. 5 Time to non-persistence with BTA
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studies, zoledronic acid patients were classified as having
short (≤90 days), medium (91–180 days), or long
(>180 days) persistence with non-persistence defined by
a therapy gap of >45 days [27, 28]. Among breast cancer
patients, those with long persistence had significantly
lower risk of skeletal complications, although there were
no significant differences between the short and medium
persistence groups [28]. Among prostate cancer patients,
however, there were no significant differences in the risk
of skeletal complications between persistence groups, al-
though more persistent patients had significantly longer
follow-up durations [27]. An earlier study by Hatoum
et al. demonstrated that in both 6 and 12 months of fol-
low-up, the rate of skeletal-related complications was sig-
nificantly lower in patients who received zoledronic acid
administrations according to the recommended dosing
schedule compared with patients who underwent less fre-
quent dosing [29]. There are currently no data available
describing the influence of compliance and persistence on
the real-world effectiveness of denosumab.
This study presents unique insights into the long-term
treatment patterns for the two most commonly used BTAs.
As with all studies, however, there are important limita-
tions. First, the study population includes only patients
who were treated at an oncology clinic which contributes
data to the OSCER database. Patients who moved or
sought care outside of these clinics would be lost to
follow-up and no longer contribute data to this data
source. As noted previously, time between bone metasta-
s i s d iagnos i s and t rea tmen t in i t i a t ion may be
underestimated since the occurrence of an SRE or BTA
initiation may trigger the recording of a bone metastasis
diagnosis and there are likely substantial delays between
the documentation of a bone metastasis diagnosis in the
patient’s medical chart and the appearance of that diagno-
sis in either the EMR or on an administrative claim re-
cord. The Kaplan-Meier analysis used to assess persis-
tence does take follow-up time into consideration.
However, mortality data were not available in the source
data, and therefore, the relationship between survival and
persistence could not be directly assessed.
Conclusions
This study is the first to examine long-term treatment patterns
for the two primary BTAs used in the US. In each of the three
1-year periods evaluated, a greater percentage of denosumab
patients were compliant compared with zoledronic acid users.
Denosumab patients also had longer durations of persistent
therapy use. These higher levels of compliance and persis-
tence may improve treatment effectiveness achieved in this
real-world setting.
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